ALL-Cause and Bleeding Costs of Patients Initiating P2Y12 Inhibitors, Fxa Inhibitors, and Dabigatran
Author(s)
Kong A1, Lee J2, Evans K3, Morrow C1, Erickson J4, Bhatt D5
1IBM Watson Health, Cambridge, MA, USA, 2PhaseBio Pharmaceuticals, Malvern, PA, USA, 3IBM Watson Health, Geneva, NY, USA, 4PhaseBio Pharmaceuticals, San Diego, CA, USA, 5Brigham and Women's Hospital, Boston, MA, USA
OBJECTIVES : Describe all-cause and bleeding-related healthcare costs among patients initiating P2Y12 inhibitors, FXa inhibitors, or dabigatran. METHODS : MarketScan commercially-insured patients initiating a P2Y12 inhibitor, FXa inhibitor, or dabigatran 1/1/2014-6/30/2018 with ≥1 year of prior baseline data with no medication use were selected. Healthcare costs were assessed during baseline and while patients were persistent on medication (initiation to the earliest of the following: day before a >30-day gap in days of supply of the medication, end of enrollment, or 6/30/2019). All-cause costs were calculated from all medical and pharmacy claims; bleeding costs were calculated from emergency room and inpatient claims with a diagnosis code for a bleed. Costs are reported per patient per year (PPPY) during the persistence period. RESULTS : Baseline mean all-cause healthcare costs were 15%-36% higher among P2Y12 patients ($54,798 +$77,590) vs. FXa ($47,456 +$93,433) and dabigatran patients ($40,364 +$81,364); baseline mean bleeding costs were similar between groups (P2Y12: $2,569 +$27,147; FXa: $2,706 +$36,901; dabigatran: $2,482 +$22,535). Baseline costs per bleeding event among P2Y12 patients ($50,575) were about 9% higher than FXa ($46,534), and 37% higher than dabigatran patients ($36,837). While persistent on their medication, P2Y12 patients had similar mean all-cause costs to dabigatran patients ($54,362 +$206,597 vs. $54,597 +$145,348 PPPY) but lower costs than FXa patients ($62,896 +$916,760), and 22%-62% higher mean bleeding costs ($2,817 +$70,083 PPPY) than FXa ($2,313 +$58,521 PPPY) and dabigatran patients ($1,739 +$42,598 PPPY). Costs per bleeding event while persistent among P2Y12 patients ($29,505) were 3% higher than FXa patients ($28,577) and 13% higher than dabigatran patients ($25,986). CONCLUSIONS : P2Y12 inhibitor patients had all-cause and bleeding-related healthcare costs similar to or greater than FXa inhibitor and dabigatran patients. The higher bleeding costs while on medication highlight the need for an effective reversal agent for P2Y12 inhibitors, which could decrease bleeding events and related costs.
Conference/Value in Health Info
2021-05, ISPOR 2021, Montreal, Canada
Value in Health, Volume 24, Issue 5, S1 (May 2021)
Code
PCV26
Topic
Economic Evaluation
Disease
Cardiovascular Disorders, Drugs